Despite high VEGFA levels in advanced PCa, anti-angiogenic therapies targeting VEGF or the VEGF receptor pathway have failed to provide significant treatment benefits in clinical trials [9, 10]. The gene discussed is VEGFA; the disease is posterior cortical atrophy.